Results 11 to 20 of about 72,228 (243)
JAK inhibitors: Ten years after
European Journal of Immunology, 2021 AbstractThe European Journal of Immunology was launched 50 years ago, coinciding with the discovery of many cytokines and growth factors and the emergence of an entirely new field of research. Ultimately, our knowledge about the biological activity of these factors allowed us to better understand how the immune system functions in the context of ...
Francesca Romana Spinelli +3 more
openaire +4 more sources
JID Innovations, 2023 Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab, tralokinumab, and nemolizumab. The increase in treatment options can be a
Masahiro Kamata, Yayoi Tada
doaj +1 more source
JAK inhibitors in autoinflammation [PDF]
Journal of Clinical Investigation, 2018 Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire +2 more sources
ACR Open Rheumatology, 2022 Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE
Muhammad Haisum Maqsood +5 more
doaj +1 more source
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by uncontrolled blood counts, constitutional symptoms, extramedullary hematopoiesis, and an increased risk of developing acute myeloid leukemia.
Andrew T. Kuykendall, Rami S. Komrokji
doaj +1 more source
New insights into IFN-γ in rheumatoid arthritis: role in the era of JAK inhibitors
Immunological Medicine, 2020 The treatment of rheumatoid arthritis (RA) is now entering a new era, the era of Janus kinase (JAK) inhibitors. JAK inhibitors target multiple cytokines including IL-6 and exhibit a beneficial treatment effect in patients with RA and inadequate response ...
Masaru Kato
doaj +1 more source
Skin Health and Disease, 2023 Background Janus kinase (JAK) inhibitors are being evaluated as promising upcoming treatments for atopic dermatitis (AD). Objectives To systematically assess the efficacy of oral JAK inhibitors in patients with AD and provide comparisons among JAK ...
Kevin P. Lee +3 more
doaj +1 more source
Life, 2023 Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE ...
Krasimir Kraev +11 more
doaj +1 more source
Network pharmacology of JAK inhibitors [PDF]
Proceedings of the National Academy of Sciences, 2016 SignificanceJAK kinase inhibitors (JAKis) have advanced options for treatment of autoimmune diseases. Because JAKs are signaling hubs for several cytokine receptors, JAKis’ overall impact on the immune system and how they actually improve diseases like rheumatoid arthritis remain poorly understood.
Devapregasan, Moodley +10 more
openaire +2 more sources
Janus-kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature [PDF]
Journal of Pediatrics Review, 2023 Background: Chronic urticaria is a long-lasting condition, sometimes with serious comorbidities, severely affecting the quality of life, which makes the patients seek efficient therapies to achieve sustained remissions.
Sepideh Darougar +2 more
doaj